| |
Choosing the right partner to deliver decentralised clinical trials is crucial. ICON has the experience and expertise to overcome the challenges in patient recruitment and retention to deliver study success. Explore ICON's DCT capabilities.
|
|
Today’s Big NewsSep 21, 2023 |
Novo Nordisk Foundation pumps $136M into new clinical cell therapy manufacturing 'hub' in Denmark Inventiva, Kezar sell Asian rights to NASH and autoimmune assets, netting $17M between them Take 3: Mesoblast plots path to market for twice-rejected cell therapy Fierce Biotech M&A Tracker 2023: Applied Molecular Transport finds a buyer; Atriva, Biocure ink reverse takeover Different roads, same destination: Study shows COVID variants evolve to suppress immunity |
|
Avoid costly manufacturing delays by establishing the identity, purity and quality of your starting materials. Download this comprehensive guide to raw materials testing. Learn more.
|
|
| By Fraiser Kansteiner Looking to establish a “hub” in the cell therapy ecosystem, the Novo Nordisk Foundation is pumping 950 million Danish kroner (about $136 million) into a new clinical production site at the Technical University of Denmark (DTU) in Lyngby. |
|
|
|
By Nick Paul Taylor Inventiva and Kezar Life Sciences have found buyers for Asian rights to their lead candidates, collectively bringing in $17 million upfront in return for the chance to develop and sell assets in certain territories. |
By Nick Paul Taylor Mesoblast has plotted a path toward its third attempt to win approval of its off-the-shelf therapy, exiting a meeting with the FDA convinced that new potency assay data and a single-arm trial can finally get the candidate to market. |
Sponsored by Rise to Health Coalition Two leaders supporting the Rise to Health Coalition discuss the need for coordinated and collective action across sectors to advance health equity |
|
BioIVT not only provides an unparalleled selection of hepatocytes, microsomes, rCYPs and other control and disease state biospecimens, but also experts to guide you to the right solution. View Biospecimens >>
|
|
By Annalee Armstrong,Max Bayer,Gabrielle Masson Fierce Biotech's M&A Tracker, your one-stop shop for dealmaking in the biopharma universe. |
By Helen Floersh In the world of COVID variants, many mutations seem to lead to the same goal: Evade innate immunity. By pinpointing key proteins that make this "convergent evolution" possible, researchers are on the way to finding new targets for therapies. |
By Ben Adams Americans' perception of the pharmaceutical industry is at its lowest point this century, especially among Republican voters, as the initial support for COVID-related efforts has turned into disillusionment. |
By Andrea Park Joining Novo Nordisk's GLP-1 assembly line is Ypsomed, which has signed on to produce “large quantities of autoinjectors” for the Danish drugmaker. |
By Nick Paul Taylor Roche has received a dressing-down for omitting important safety information from a cancer drug dosing webpage. A U.K. self-regulatory body concluded Roche brought discredit upon, and reduced confidence in, the pharmaceutical industry by failing to provide information that is important to patient safety. |
By Anastassia Gliadkovskaya OutCare Health is known for its OutList, an extensive directory of LBGTQ+ affirming providers. Data automation company Veda will ingest that information and offer it to payer clients. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
October 16-18, 2023 | Boston, MA Brought to you by the editors behind Fierce Biotech, this conference is a unique venue where biotech executives can network and learn how to improve their partnership and pipeline strategies. It’s the only event that covers the entire pharma R&D spectrum, from basic research through clinical trials. Countdown is on! Register today to save $200
|
|
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WhitepaperLearn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| Whitepaper15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
